# Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT02227901** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **DRUG:** Tipifarnib
- **RADIATION:** External Beam Radiation Therapy
- **DRUG:** Temozolomide
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02227901
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2007-06
- **Final completion:** 2014-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227901, "Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02227901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*